Literature DB >> 25454831

Differences in pre-operative treatment for rectal cancer between Norway, Sweden, Denmark, Belgium and the Netherlands.

C B M van den Broek1, W van Gijn1, E Bastiaannet2, B Møller3, R Johansson4, M A G Elferink5, A Wibe6, L Påhlman7, L H Iversen8, F Penninckx9, V Valentini10, C J H van de Velde11.   

Abstract

Several studies have shown remarkable differences in colorectal cancer survival across Europe. Most of these studies lacked information about stage and treatment. In this study we compared short-term survival as well as differences in tumour stage and treatment strategies between five European countries: Norway, Sweden, Denmark, Belgium, and the Netherlands. For this retrospective cohort study all patients aged 18 years or older and operated on adenocarcinoma of the rectum without distant metastases and diagnosed in 2008 and 2009 were selected in national audit registries from Norway, Sweden, Denmark, Belgium, and the Netherlands. Differences in pre-operative treatment between the countries were compared using univariable and multivariable logistic regression. One year relative survival and one year relative excess risk of death (RER) were compared between the five countries. Large variation in the use of preoperative radiotherapy and chemoradiation was found between the countries. Even though, there was little variation in relative survival between the countries, except Sweden, which had a significant better one year RER of death among the elderly patients after adjustment. The differences in survival are expected to be caused by differences in peri-operative care, selection of patients, and especially management of elderly patients. The effects of preoperative treatment are expected to be seen on long term follow-up.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Audit; Mortality; Population-based; Preoperative treatment; Quality assurance; Rectal neoplasms

Mesh:

Year:  2014        PMID: 25454831     DOI: 10.1016/j.ejso.2014.09.011

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  7 in total

1.  Surgery: palliative primary tumour resection in mCRC-debate continues.

Authors:  Cornelis J H van de Velde
Journal:  Nat Rev Clin Oncol       Date:  2015-01-20       Impact factor: 66.675

2.  Cancer Center Volume and Type Impact Stage-Specific Utilization of Neoadjuvant Therapy in Rectal Cancer.

Authors:  Emily F Midura; Andrew D Jung; Meghan C Daly; Dennis J Hanseman; Bradley R Davis; Shimul A Shah; Ian M Paquette
Journal:  Dig Dis Sci       Date:  2017-05-13       Impact factor: 3.199

3.  Neoadjuvant Therapy in Rectal Cancer Patients With Clinical Stage II to III Across European Countries: Variations and Outcomes.

Authors:  Masoud Babaei; Lina Jansen; Yesilda Balavarca; Annika Sjövall; Amanda Bos; Tony van de Velde; Michel Moreau; Gabriel Liberale; Ana Filipa Gonçalves; Maria José Bento; Cornelia M Ulrich; Petra Schrotz-King; Valery Lemmens; Bengt Glimelius; Hermann Brenner
Journal:  Clin Colorectal Cancer       Date:  2017-09-28       Impact factor: 4.481

4.  Is there a need for neoadjuvant short-course radiotherapy in T3 rectal cancer with positive lymph node involvement? A single-center retrospective cohort study.

Authors:  Minna Räsänen; Laura Renkonen-Sinisalo; Harri Mustonen; Anna Lepistö
Journal:  World J Surg Oncol       Date:  2019-08-08       Impact factor: 2.754

5.  Colon cancer patients with a serious psychiatric disorder present with a more advanced cancer stage and receive less adjuvant chemotherapy - A Nationwide Danish Cohort Study.

Authors:  Linda Kaerlev; Maria Iachina; Oleg Trosko; Niels Qvist; Pernille Møller Ljungdalh; Bente Mertz Nørgård
Journal:  BMC Cancer       Date:  2018-10-29       Impact factor: 4.430

6.  Survival by colon cancer stage and screening interval in Lynch syndrome: a prospective Lynch syndrome database report.

Authors:  Mev Dominguez-Valentin; Toni T Seppälä; Julian R Sampson; Finlay Macrae; Ingrid Winship; D Gareth Evans; Rodney J Scott; John Burn; Gabriela Möslein; Inge Bernstein; Kirsi Pylvänäinen; Laura Renkonen-Sinisalo; Anna Lepistö; Annika Lindblom; John-Paul Plazzer; Douglas Tjandra; Huw Thomas; Kate Green; Fiona Lalloo; Emma J Crosbie; James Hill; Gabriel Capella; Marta Pineda; Matilde Navarro; Joan Brunet Vidal; Karina Rønlund; Randi Thyregaard Nielsen; Mette Yilmaz; Louise Laurberg Elvang; Lior Katz; Maartje Nielsen; Sanne W Ten Broeke; Sigve Nakken; Eivind Hovig; Lone Sunde; Matthias Kloor; Magnus V Knebel Doeberitz; Aysel Ahadova; Noralane Lindor; Verena Steinke-Lange; Elke Holinski-Feder; Jukka-Pekka Mecklin; Pål Møller
Journal:  Hered Cancer Clin Pract       Date:  2019-10-14       Impact factor: 2.857

7.  Radiotherapy regimens for rectal cancer: long-term outcomes and health-related quality of life in the Stockholm III trial.

Authors:  Johan Erlandsson; Stina Fuentes; Calin Radu; Jan-Erik Frödin; Hemming Johansson; Yvonne Brandberg; Torbjörn Holm; Bengt Glimelius; Anna Martling
Journal:  BJS Open       Date:  2021-11-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.